Evaluation and treatment of the patient coinfected with hepatitis B and HIV

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalCurrent HIV/AIDS Reports
Volume5
Issue number3
DOIs
StatePublished - Aug 2008

Fingerprint

Hepatitis B
Hepatitis B virus
HIV
Therapeutics
DNA
Coinfection
Population
Liver Diseases
Survival
Mortality

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Evaluation and treatment of the patient coinfected with hepatitis B and HIV. / Kitchell, Ellen; Jain, Mamta K.

In: Current HIV/AIDS Reports, Vol. 5, No. 3, 08.2008, p. 103-111.

Research output: Contribution to journalArticle

@article{ae9900c9c956419faaebd8a1aae18b05,
title = "Evaluation and treatment of the patient coinfected with hepatitis B and HIV",
abstract = "Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.",
author = "Ellen Kitchell and Jain, {Mamta K.}",
year = "2008",
month = "8",
doi = "10.1007/s11904-008-0017-1",
language = "English (US)",
volume = "5",
pages = "103--111",
journal = "Current Alzheimer Research",
issn = "1531-0035",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Evaluation and treatment of the patient coinfected with hepatitis B and HIV

AU - Kitchell, Ellen

AU - Jain, Mamta K.

PY - 2008/8

Y1 - 2008/8

N2 - Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

AB - Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

UR - http://www.scopus.com/inward/record.url?scp=48949102249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48949102249&partnerID=8YFLogxK

U2 - 10.1007/s11904-008-0017-1

DO - 10.1007/s11904-008-0017-1

M3 - Article

C2 - 18627658

AN - SCOPUS:48949102249

VL - 5

SP - 103

EP - 111

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1531-0035

IS - 3

ER -